Search

Your search keyword '"Khan, Hina N."' showing total 24 results
Start Over Author "Khan, Hina N."
24 results on '"Khan, Hina N."'

1. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation

Author

Pasvolsky, Oren, Wang, Zhongya, Milton, Denái R., Tanner, Mark R., Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Tang, Guilin, Kebriaei, Partow, Aljawai, Yosra, Khan, Hina N., Lee, Hans C., Ye, Christine, Patel, Krina K., Thomas, Sheeba K., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., and Qazilbash, Muzaffar H.

Published
2024
Full Text
View/download PDF

2. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience

Author

Pasvolsky, Oren, Ghanem, Sassine, Milton, Denái R., Rauf, Mikael, Tanner, Mark R., Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Tang, Guilin, Aljawai, Yosra, Khan, Hina N., Kebriaei, Partow, Lee, Hans C., Patel, Krina K., Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., and Qazilbash, Muzaffar H.

Published
2024
Full Text
View/download PDF

3. Long-Term Responders after Upfront Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma

Author

Pasvolsky, Oren, primary, Wang, Zhongya, additional, Milton, Denai R., additional, Khan, Hina N., additional, Tanner, Mark R., additional, Bashir, Qaiser, additional, Srour, Samer A., additional, Saini, Neeraj Y., additional, Lin, Paul, additional, Ramdial, Jeremy, additional, Nieto, Yago, additional, Aljawai, Yosra, additional, Ansari, Alihussain, additional, Lee, Hans C., additional, Patel, Krina K., additional, Kebriaei, Partow, additional, Thomas, Sheeba K., additional, Weber, Donna M., additional, Orlowski, Robert Z., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2024
Full Text
View/download PDF

4. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.

Author

Pasvolsky, Oren, Pasyar, Sarah, Bassett, Roland L., Khan, Hina N., Tanner, Mark R., Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Lee, Hans C., Patel, Krina K., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., and Qazilbash, Muzaffar H.

Subjects
HEMATOPOIETIC stem cell transplantation, MULTIPLE myeloma
Abstract

Background: The prognostic significance of minimal residual disease (MRD) status before autologous hematopoietic stem cell transplantation (autoHCT) in patients with multiple myeloma (MM) has not been clearly elucidated. Methods: Retrospective single‐center study of adult MM patients who achieved ≥very good partial response (VGPR) after induction therapy from 2015 to 2021 received upfront autoHCT and had available pretransplant MRD status by next‐generation flow cytometry. The cohort was divided into pretransplant MRD‐negative (MRDneg) and MRD‐positive (MRDpos) groups. Results: A total of 733 patients were included in our analysis; 425 were MRDneg and 308 MRDpos at autoHCT. In the MRDpos group, more patients had high‐risk cytogenetic abnormalities (48% vs. 38%, respectively; p =.025), whereas fewer patients achieved ≥CR before autoHCT (14% vs. 40%; p <.001). At day 100 after autoHCT, 37% of the MRDpos versus 71% of the MRDneg achieved ≥CR, and at best posttransplant response 65% versus 88% achieved ≥CR, respectively. After a median follow‐up of 27.6 months (range, 0.7–82.3), the median PFS was significantly shorter for patients in the MRDpos group compared to the MRDneg group: 48.2 months (95% confidence interval [CI], 0.3–80.5) versus 80.1 months (95% CI, 0.5–80.1), respectively (p <.001). There was no significant difference in overall survival between the two groups (p =.41). Pretransplant MRDpos status was predictive of shorter PFS in multivariate analysis (hazard ratio, 1.80; 95% CI, 1.31–2.46; p <.001). The impact of pretransplant MRD status was retained in most of the examined subgroups. Conclusions: In patients achieving ≥VGPR to induction, pretransplant MRDpos status was associated with a lower CR rate after autoHCT and a shorter PFS. This retrospective single‐center study evaluated the prognostic impact of pretransplant minimal residual disease (MRD) status by next‐generation flow cytometry in 733 multiple myeloma patients who achieved ≥ very good partial response after induction therapy and received upfront autologous hematopoietic stem cell transplantation (autoHCT). Pretransplant MRD positivity was associated with a lower complete remission rate after autoHCT and a shorter progression‐free survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation

Author

Pasvolsky, Oren, primary, Pasyar, Sarah, additional, Bassett, Roland L., additional, Khan, Hina N., additional, Tanner, Mark R., additional, Bashir, Qaiser, additional, Srour, Samer, additional, Saini, Neeraj, additional, Lin, Paul, additional, Ramdial, Jeremy, additional, Nieto, Yago, additional, Lee, Hans C., additional, Patel, Krina K., additional, Kebriaei, Partow, additional, Thomas, Sheeba K., additional, Weber, Donna M., additional, Orlowski, Robert Z., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2023
Full Text
View/download PDF

8. Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies

Author

Hoefnagel, Sanne J. M., primary, Koemans, Willem J., additional, Khan, Hina N., additional, Koster, Jan, additional, Meijer, Sybren L., additional, van Dieren, Jolanda M., additional, Kodach, Liudmila L., additional, van Sandick, Johanna W., additional, Calpe, Silvia, additional, del Sancho-Serra, Carmen M., additional, Correia, Ana C. P., additional, Van Berge Henegouwen, Mark I., additional, Gisbertz, Suzanne S., additional, Hulshof, Maarten C. C. M., additional, Mattioli, Sandro, additional, Spaander, Manon C. W., additional, and Krishnadath, Kausilia K., additional

Published
2022
Full Text
View/download PDF

9. Soluble guanylate cyclase activator BAY 54–6544 improves vasomotor function and survival in an accelerated ageing mouse model

Author

Ataei Ataabadi, Ehsan, primary, Golshiri, Keivan, additional, Jüttner, Annika A., additional, de Vries, René, additional, Van den Berg‐Garrelds, Ingrid, additional, Nagtzaam, Nicole M. A., additional, Khan, Hina N., additional, Leijten, Frank P. J., additional, Brandt, Renata M. C., additional, Dik, Willem A., additional, van der Pluijm, Ingrid, additional, Danser, A. H. Jan, additional, Sandner, Peter, additional, and Roks, Anton J. M., additional

Published
2022
Full Text
View/download PDF

10. The Long Non-Coding Antisense RNA JHDM1D-AS1 Regulates Inflammatory Responses in Human Monocytes

Author

Malmström, Erik, primary, Khan, Hina N., additional, Veer, Cornelis van ‘t, additional, Stunnenberg, Melissa, additional, Meijer, Mariska T., additional, Matsumoto, Hisatake, additional, Otto, Natasja A., additional, Geijtenbeek, Teunis B. H., additional, de Vos, Alex F., additional, Poll, Tom van der, additional, and Scicluna, Brendon P., additional

Published
2022
Full Text
View/download PDF

11. Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies

Author

Hoefnagel, Sanne J. M., Koemans, Willem J., Khan, Hina N., Koster, Jan, Meijer, Sybren L., van Dieren, Jolanda M., Kodach, Liudmila L., van Sandick, Johanna W., Calpe, Silvia, del Sancho-Serra, Carmen M., Correia, Ana C. P., Henegouwen, Mark I. Van Berge, Gisbertz, Suzanne S., Hulshof, Maarten C. C. M., Mattioli, Sandro, Spaander, Manon C. W., Krishnadath, Kausilia K., Hoefnagel, Sanne J. M., Koemans, Willem J., Khan, Hina N., Koster, Jan, Meijer, Sybren L., van Dieren, Jolanda M., Kodach, Liudmila L., van Sandick, Johanna W., Calpe, Silvia, del Sancho-Serra, Carmen M., Correia, Ana C. P., Henegouwen, Mark I. Van Berge, Gisbertz, Suzanne S., Hulshof, Maarten C. C. M., Mattioli, Sandro, Spaander, Manon C. W., and Krishnadath, Kausilia K.

Abstract

Esophageal adenocarcinoma (EAC) is a highly aggressive cancer and its response to chemo- and radiotherapy is unpredictable. EACs are highly heterogeneous at the molecular level. The aim of this study was to perform gene expression analysis of EACs to identify distinct molecular subgroups and to investigate expression signatures in relation to treatment response. In this prospective observational study, RNA sequencing was performed on pre-treatment endoscopic EAC biopsies from a discovery cohort included between 2012 and 2017 in one Dutch Academic Center. Four additional cohorts were analyzed for validation purposes. Unsupervised clustering was performed on 107 patients to identify biological EAC subgroups. Specific cell signaling profiles were identified and evaluated with respect to predicting response to neo-adjuvant chemo(radio)therapy. We identified and validated three distinct biological EAC subgroups, characterized by (1) p38 MAPK/Toll-like receptor signaling; (2) activated immune system; and (3) impaired cell adhesion. Subgroup 1 was associated with poor response to chemo-radiotherapy. Moreover, an immune signature with activated T-cell signaling, and increased number of activated CD4 T memory cells, neutrophils and dendritic cells, and decreased M1 and M2 macrophages and plasma cells, was associated with complete histopathological response. This study provides a novel molecular classification for EACs. EAC subgroup 1 proved to be more therapy-resistant, while immune signaling was increased in patients with complete response to chemo-radiotherapy. Our findings give insight into the biology of EACs and in cellular signaling mechanisms underlying response to neo-adjuvant treatment. Future implementation of this classification will improve patient stratification and enhance the development of targeted therapies.

Published
2022

12. Systems biology of the host response to severe infection

Author

Khan, Hina N., van der Poll, Tom, Zwinderman, Koos, Scicluna, Brendon, Center of Experimental and Molecular Medicine, AII - Infectious diseases, ANS - Neuroinfection & -inflammation, and Graduate School

Published
2022

13. HIVEP1 Is a Negative Regulator of NF-κB That Inhibits Systemic Inflammation in Sepsis

Author

Matsumoto, Hisatake, primary, Scicluna, Brendon P., additional, Jim, Kin Ki, additional, Falahi, Fahimeh, additional, Qin, Wanhai, additional, Gürkan, Berke, additional, Malmström, Erik, additional, Meijer, Mariska T., additional, Butler, Joe M., additional, Khan, Hina N., additional, Takagi, Tsuyoshi, additional, Ishii, Shunsuke, additional, Schultz, Marcus J., additional, van de Beek, Diederik, additional, de Vos, Alex F., additional, van ‘t Veer, Cornelis, additional, and van der Poll, Tom, additional

Published
2021
Full Text
View/download PDF

14. Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

Author

Pasvolsky, Oren, Pasyar, Sarah, Bassett, Roland L., Khan, Hina N., Tanner, Mark R., Bashir, Qaiser, Srour, Samer A., Saini, Neeraj Y., Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Lee, Hans C., Patel, Krina K., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., and Qazilbash, Muzaffar H.

Published
2023
Full Text
View/download PDF

15. Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Author

Qazilbash, Muzaffar H., Khan, Hina N., Milton, Denái R., Pasvolsky, Oren, Tanner, Mark R., Popat, Uday R., Kebriaei, Partow, Hosing, Chitra, Khouri, Issa F., Rezvani, Katayoun, Nieto, Yago, Oran, Betul, Srour, Samer A., Saini, Neeraj Y., Olson, Amanda L., Ahmed, Sairah, Alatrash, Gheath, Rondon, Gabriela, Konopleva, Marina Y., Champlin, Richard E., Shpall, Elizabeth J., Bashir, Qaiser, and Pemmaraju, Naveen

Published
2023
Full Text
View/download PDF

16. Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience

Author

Pasvolsky, Oren, Ghanem, Sassine, Milton, Denái R., Rauf, Mikael, Tanner, Mark R., Bashir, Qaiser, Srour, Samer A., Saini, Neeraj Y., Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Khan, Hina N., Kebriaei, Partow, Lee, Hans C., Patel, Krina K., Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., and Qazilbash, Muzaffar H.

Published
2023
Full Text
View/download PDF

19. Gene expression profiles of esophageal squamous cell cancers in Hodgkin lymphoma survivors versus sporadic cases

Author

Ykema, Berbel L. M., Hoefnagel, Sanne J. M., Rigter, Lisanne S., Kodach, Liudmila L., Meijer, Gerrit A., van Leeuwen, Flora E., Khan, Hina N., Snaebjornsson, Petur, Aleman, Berthe M. P., Broeks, Annegien, Meijer, Sybren L., Wang, Kenneth K., Carvalho, Beatriz, Krishnadath, Kausilia K., vanLeerdam, Monique E., Meijer, S. L., Hulshof, M. C. C. M., Geijsen, E. D., van Laarhoven, H. W. M., van Berge Henegouwen, M. I., Gisbertz, S. S., Pathology, Epidemiology and Data Science, Surgery, VU University medical center, CCA - Cancer biology and immunology, Graduate School, Amsterdam Gastroenterology Endocrinology Metabolism, Gastroenterology and Hepatology, Radiotherapy, and Oncology

Subjects
Oncology, Male, Esophageal Neoplasms, Molecular biology, medicine.medical_treatment, Cancer Treatment, Gene Expression, Sequencing techniques, Mathematical and Statistical Techniques, Cancer Survivors, Gene expression, Breast Tumors, Medicine and Health Sciences, Aged, 80 and over, Principal Component Analysis, Multidisciplinary, Statistics, RNA sequencing, Middle Aged, Hodgkin Disease, Esophageal Tissue, Gene Expression Regulation, Neoplastic, medicine.anatomical_structure, Physical Sciences, Carcinoma, Squamous Cell, Medicine, Female, Research Article, Signal Transduction, Clinical Oncology, Adult, medicine.medical_specialty, Science, Radiation Therapy, Young Adult, Downregulation and upregulation, Internal medicine, Breast Cancer, medicine, Genetics, Humans, Squamous Cell Carcinoma, Esophagus, Statistical Methods, Aged, Colorectal Cancer, Squamous cell cancer, Biology and life sciences, business.industry, Carcinoma, RNA, Cancers and Neoplasms, Radiation therapy, Research and analysis methods, Molecular biology techniques, Multivariate Analysis, Hodgkin lymphoma, Clinical Medicine, business, Transcriptome, Mathematics
Abstract

Hodgkin lymphoma (HL) survivors are at increased risk of developing second primary esophageal squamous cell cancer (ESCC). We aimed to gain insight in the driving events of ESCC in HL survivors (hESCC) by using RNA sequencing and NanoString profiling. Objectives were to investigate differences in RNA signaling between hESCC and sporadic ESCC (sESCC), and to look for early malignant changes in non-neoplastic esophageal tissue of HL survivors (hNN-tissue). We analyzed material of 26 hESCC cases, identified via the Dutch pathology registry (PALGA) and 17 sESCC cases from one academic institute and RNA sequencing data of 44 sESCC cases from TCGA. Gene expression profiles for the NanoString panel PanCancer IO 360 were obtained from 16/26 hESCC and four hNN-tissue, while non-neoplastic squamous tissue of four sporadic cases (sNN-tissue) served as reference profile. Hierarchical clustering, differential expression and pathway analyses were performed. Overall, the molecular profiles of hESCC and sESCC were similar. There was increased immune, HMGB1 and ILK signaling compared to sNN-tissue. The profiles of hNN-tissue were distinct from sNN-tissue, indicating early field effects in the esophagus of HL survivors. The BRCA1 pathway was upregulated in hESCC tissue, compared to hNN tissue. Analysis of expression profiles reveals overlap between hESCC and sESCC, and differences between hESCC and its surrounding hNN-tissue. Further research is required to validate our results and to investigate whether the changes observed in hNN-tissue are already detectable before development of hESCC. In the future, our findings could be used to improve hESCC patient management.

Published
2020
Full Text
View/download PDF

20. The circulatory small non-coding RNA landscape in community-acquired pneumonia on intensive care unit admission

Author

Medische Staf Intensive Care, Infection & Immunity, Epi Infectieziekten, JC onderzoeksprogramma Infectieziekten, Khan, Hina N, Jongejan, Aldo, van Vught, Lonneke A, Horn, Janneke, Schultz, Marcus J, Zwinderman, Aeilko H, Cremer, Olaf L, Bonten, Marc J, van der Poll, Tom, Scicluna, Brendon P, Medische Staf Intensive Care, Infection & Immunity, Epi Infectieziekten, JC onderzoeksprogramma Infectieziekten, Khan, Hina N, Jongejan, Aldo, van Vught, Lonneke A, Horn, Janneke, Schultz, Marcus J, Zwinderman, Aeilko H, Cremer, Olaf L, Bonten, Marc J, van der Poll, Tom, and Scicluna, Brendon P

Published
2021

22. Leukocyte transcriptional signatures dependent on LPS dosage in human endotoxemia

Author

Khan, Hina N., Perlee, Desiree, Schoenmaker, Lieke, Van Der Meer, Anne-Jan, Franitza, Marek, Toliat, Mohammad Reza, Nuernberg, Peter, Zwinderman, Aeilko H., van Der Poll, Tom, Scicluna, Brendon P., Khan, Hina N., Perlee, Desiree, Schoenmaker, Lieke, Van Der Meer, Anne-Jan, Franitza, Marek, Toliat, Mohammad Reza, Nuernberg, Peter, Zwinderman, Aeilko H., van Der Poll, Tom, and Scicluna, Brendon P.

Abstract

The host immune response is characterized by a complex interplay of signal-specific cellular transcriptional responses. The magnitude of the immune response is dependent on the strength of the external stimulus. Knowledge on leukocyte transcriptional responses altered in response to different stimulus dosages in man is lacking. Here, we sought to identify leukocyte transcriptional signatures dependent on LPS dose in humans. Healthy human volunteers were administered 1 ng/kg (n = 7), 2 ng/kg (n = 6), or 4 ng/kg (n = 7) LPS intravenously. Blood was collected before (pre-LPS) and 4 h after LPS administration. Total RNA was analyzed by microarrays and generalized linear models. Pathway analysis was performed by using Ingenuity pathway analysis. Leukocyte transcriptomes altered per LPS dosage were predominantly shared, with 47% common signatures relative to pre-LPS. A univariate linear model identified a set of 3736 genes that exhibited a dependency on differing LPS dosages. Neutrophil, monocyte, and lymphocyte counts explained 38.9% of the variance in the LPS dose-dependent gene set. A multivariate linear model including leukocyte composition delineated a set of 295 genes with a dependency on LPS dose. Evaluation of the 295 gene signature in patients with sepsis due to abdominal infections showed significant correlations. Promoter regions of the LPS dose gene set were enriched for YY1, EGR1, ELK1, GABPA, KLF4, and REL transcription factor binding sites. Intravenous injection of 1, 2, or 4 ng/kg LPS was accompanied by both shared and distinct leukocyte transcriptional alterations. These data may assist in assessing the severity of the insult in patients with abdominal sepsis.

Published
2019

24. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.

Author

Marcoux, Curtis, Pasyar, Sarah, Milton, Denái R., Khan, Hina N., Tanner, Mark R., Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Neupane, Niraj, Lee, Hans C., Patel, Krina K., Tang, Guilin, Aljawai, Yosra, Kebriaei, Partow, Thomas, Sheeba K., Orlowski, Robert Z., and Shpall, Elizabeth J.

Subjects
*HEMATOPOIETIC stem cell transplantation, *IMMUNOGLOBULIN light chains, *HEMATOPOIETIC stem cells, *STEM cell transplantation, *CELL transplantation, *MEDICAL registries
Abstract

The article explores the impact of body mass index (BMI) on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. The study included a large cohort of patients with varying BMIs and analyzed progression-free survival, overall survival, haematological response, and measurable residual disease status. The findings suggest that elevated BMI did not adversely affect survival outcomes, including in patients with severe obesity, indicating that BMI may not significantly impact eligibility for auto-HCT in multiple myeloma patients. The study acknowledges limitations of retrospective analysis but provides valuable insights into the relationship between BMI and treatment outcomes in this patient population. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results